Read in Spanish
In a resolution taken this February 13, the member countries of the European Union (MEPs) adopted guidelines in which they are exhorted to the national authorities to close the gaps that exist with respect to the medicinal use of cannabis.
To this end, the resolution urges members to resolve the regulatory, economic and cultural barriers that weigh on scientific research.
This line goes hand in hand with the commitment of the European Union (EU) to stimulate more research projects to take advantage of the potential to create medicines based on cannabis.
This was announced by the EU in a press release that also specifically delineates the lines of action to be taken:
Let doctors prescribe this type of medicine
The regulation of cannabis-based medicines will mean for the local authorities, health and profits, the MEPS, also limit the black market to ensure quality, labels and, in turn, access to minors.
At start-up, member states are called upon to use their professional knowledge to prescribe this type of medicine when it is effective. In the event that it is an advisable treatment, health systems should cover it, the statement said.
Medical evidence is undeniable
Because the World Health Organization (WHO) recommended that the cannabinoids Tetrahydrocannabinol (THC) and cannabidiol (CBD), should be reclassified by the health authorities of the countries, motivates the reaction of the EU to adopt a homogeneous line when there is talk of medicinal use of the plant.
The MEPS says that there is evidence that cannabis can help the symptoms of mental disorders such as psychosis, tourette syndrome, as well as, help epilepsy, arthritis, cancer, asthma, glaucoma, Crohn’s disease. It is also effective in increasing appetite in sick people with HIV.
Read the official press release of the European Parliament: https://bit.ly/2SdRufL
Follow us on instagram: @mcnglobal